Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 4 days ago

Contineum Therapeutics, Inc.: BALYASNY ASSET MANAGEMENT L.P. amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Balyasny Asset Management L.P. amended its Schedule 13G stake filing for Contineum Therapeutics, Inc., disclosing the change in a filing with the U.S. Securities and Exchange Commission under accession number 0001172661-26-005041. The amendment updates the asset manager's previously reported beneficial ownership position in the clinical-stage biopharmaceutical company. Schedule 13G filings are required of investors holding passive stakes above 5% of a class of equity securities, so the revision signals a shift in Balyasny's holdings. The filing did not specify the size or direction of the change in the headline disclosure. Investors will watch for the amended figures to gauge whether the asset manager increased, trimmed or maintained its position in Contineum.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Contineum Therapeutics, Inc., Balyasny Asset Management L.P.